Literature DB >> 26194852

Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches.

Rino Ragno1, Flavio Ballante, Adele Pirolli, Richard B Wickersham, Alexandros Patsilinakos, Stéphanie Hesse, Enrico Perspicace, Gilbert Kirsch.   

Abstract

Vascular endothelial growth factor receptor-2, (VEGFR-2), is a key element in angiogenesis, the process by which new blood vessels are formed, and is thus an important pharmaceutical target. Here, 3-D quantitative structure-activity relationship (3-D QSAR) were used to build a quantitative screening and pharmacophore model of the VEGFR-2 receptors for design of inhibitors with improved activities. Most of available experimental data information has been used as training set to derive optimized and fully cross-validated eight mono-probe and a multi-probe quantitative models. Notable is the use of 262 molecules, aligned following both structure-based and ligand-based protocols, as external test set confirming the 3-D QSAR models' predictive capability and their usefulness in design new VEGFR-2 inhibitors. From a survey on literature, this is the first generation of a wide-ranging computational medicinal chemistry application on VEGFR2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26194852     DOI: 10.1007/s10822-015-9859-y

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  49 in total

Review 1.  Postnatal vasculogenesis.

Authors:  D Ribatti; A Vacca; B Nico; L Roncali; F Dammacco
Journal:  Mech Dev       Date:  2001-02       Impact factor: 1.882

2.  Ligand-based structural hypotheses for virtual screening.

Authors:  Ajay N Jain
Journal:  J Med Chem       Date:  2004-02-12       Impact factor: 7.446

3.  HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.

Authors:  Rino Ragno; Simona Frasca; Fabrizio Manetti; Antonella Brizzi; Silvio Massa
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

4.  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

Authors:  Brian L Hodous; Stephanie D Geuns-Meyer; Paul E Hughes; Brian K Albrecht; Steve Bellon; James Bready; Sean Caenepeel; Victor J Cee; Stuart C Chaffee; Angela Coxon; Maurice Emery; Jenne Fretland; Paul Gallant; Yan Gu; Doug Hoffman; Rebecca E Johnson; Richard Kendall; Joseph L Kim; Alexander M Long; Michael Morrison; Philip R Olivieri; Vinod F Patel; Anthony Polverino; Paul Rose; Paul Tempest; Ling Wang; Douglas A Whittington; Huilin Zhao
Journal:  J Med Chem       Date:  2007-01-25       Impact factor: 7.446

5.  Exploring novel KDR inhibitors based on pharmaco-informatics methodology.

Authors:  R K Kar; P Suryadevara; B R Sahoo; G C Sahoo; M R Dikhit; P Das
Journal:  SAR QSAR Environ Res       Date:  2013-02-25       Impact factor: 3.000

6.  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Authors:  F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

7.  Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.

Authors:  H Gille; J Kowalski; B Li; J LeCouter; B Moffat; T F Zioncheck; N Pelletier; N Ferrara
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

8.  De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction.

Authors:  Yanmin Zhang; Haichun Liu; Yu Jiao; Haoliang Yuan; Fengxiao Wang; Shuai Lu; Sihui Yao; Zhipeng Ke; Wenting Tai; Yulei Jiang; Yadong Chen; Tao Lu
Journal:  Mol Divers       Date:  2012-10-23       Impact factor: 2.943

9.  Pharmacophore and docking-based combined in-silico study of KDR inhibitors.

Authors:  F A Pasha; M Muddassar; M M Neaz; Seung Joo Cho
Journal:  J Mol Graph Model       Date:  2009-04-19       Impact factor: 2.518

10.  Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.

Authors:  Juan Du; Beilei Lei; Jin Qin; Huanxiang Liu; Xiaojun Yao
Journal:  J Mol Graph Model       Date:  2008-11-05       Impact factor: 2.518

View more
  3 in total

1.  Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.

Authors:  Manuela Sabatino; Dante Rotili; Alexandros Patsilinakos; Mariantonietta Forgione; Daniela Tomaselli; Fréderic Alby; Paola B Arimondo; Antonello Mai; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2018-01-15       Impact factor: 3.686

2.  Identification of Inhibitors to Trypanosoma cruzi Sirtuins Based on Compounds Developed to Human Enzymes.

Authors:  Tanira Matutino Bastos; Milena Botelho Pereira Soares; Caio Haddad Franco; Laura Alcântara; Lorenzo Antonini; Manuela Sabatino; Nicola Mautone; Lucio Holanda Freitas-Junior; Carolina Borsoi Moraes; Rino Ragno; Dante Rotili; Sergio Schenkman; Antonello Mai; Nilmar Silvio Moretti
Journal:  Int J Mol Sci       Date:  2020-05-22       Impact factor: 5.923

3.  The Targeted Pesticides as Acetylcholinesterase Inhibitors: Comprehensive Cross-Organism Molecular Modelling Studies Performed to Anticipate the Pharmacology of Harmfulness to Humans In Vitro.

Authors:  Milan Mladenović; Biljana B Arsić; Nevena Stanković; Nezrina Mihović; Rino Ragno; Andrew Regan; Jelena S Milićević; Tatjana M Trtić-Petrović; Ružica Micić
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.